Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position.

Cousin D, Hummersone MG, Bradshaw TD, Zhang J, Moody CJ, Foreiter MB, Summers HS, Lewis W, Wheelhouse RT, Stevens MFG.

Medchemcomm. 2018 Jan 19;9(3):545-553. doi: 10.1039/c7md00554g. eCollection 2018 Mar 1.

2.

Corrigendum to "Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands" [Canc. Lett. 403 (2017) 98-107].

Allison SJ, Sadiq M, Baronou E, Cooper PA, Dunnill C, Georgopoulos NT, Latif A, Shepherd S, Shnyder SD, Stratford IJ, Wheelhouse RT, Willans CE, Phillips RM.

Cancer Lett. 2018 Sep 1;431:247. doi: 10.1016/j.canlet.2018.06.022. Epub 2018 Jun 19. No abstract available.

3.

Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells.

Allison SJ, Cooke D, Davidson FS, Elliott PIP, Faulkner RA, Griffiths HBS, Harper OJ, Hussain O, Owen-Lynch PJ, Phillips RM, Rice CR, Shepherd SL, Wheelhouse RT.

Angew Chem Int Ed Engl. 2018 Jul 26;57(31):9799-9804. doi: 10.1002/anie.201805510. Epub 2018 Jul 3.

PMID:
29863754
4.

Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.

Allison SJ, Sadiq M, Baronou E, Cooper PA, Dunnill C, Georgopoulos NT, Latif A, Shepherd S, Shnyder SD, Stratford IJ, Wheelhouse RT, Willans CE, Phillips RM.

Cancer Lett. 2017 Sep 10;403:98-107. doi: 10.1016/j.canlet.2017.04.041. Epub 2017 Jun 15. Erratum in: Cancer Lett. 2018 Sep 1;431:247.

5.

Stabilization of a Bimolecular Triplex by 3'-S-Phosphorothiolate Modifications: An NMR and UV Thermal Melting Investigation.

Evans K, Bhamra I, Wheelhouse RT, Arnold JR, Cosstick R, Fisher J.

Chemistry. 2015 May 4;21(19):7278-84. doi: 10.1002/chem.201500369. Epub 2015 Mar 20.

6.

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

Ramirez YP, Mladek AC, Phillips RM, Gynther M, Rautio J, Ross AH, Wheelhouse RT, Sakaria JN.

Mol Cancer Ther. 2015 Jan;14(1):111-9. doi: 10.1158/1535-7163.MCT-14-0113. Epub 2014 Oct 28.

7.

The medicinal chemistry of imidazotetrazine prodrugs.

Moody CL, Wheelhouse RT.

Pharmaceuticals (Basel). 2014 Jul 10;7(7):797-838. doi: 10.3390/ph7070797.

8.

Glioblastoma multiforme therapy and mechanisms of resistance.

Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH.

Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506. doi: 10.3390/ph6121475.

9.

Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.

Pletsas D, Garelnabi EA, Li L, Phillips RM, Wheelhouse RT.

J Med Chem. 2013 Sep 12;56(17):7120-32. doi: 10.1021/jm401121k. Epub 2013 Aug 16.

10.

Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.

Garelnabi EA, Pletsas D, Li L, Kiakos K, Karodia N, Hartley JA, Phillips RM, Wheelhouse RT.

ACS Med Chem Lett. 2012 Sep 18;3(12):965-8. doi: 10.1021/ml300132t. eCollection 2012 Dec 13.

11.

Minor structural modifications to alchemix influence mechanism of action and pharmacological activity.

Abdallah QM, Phillips RM, Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse RT, Kiakos K, Bingham JP, Hartley JA, Patterson LH, Pors K.

Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. doi: 10.1016/j.bcp.2012.02.017. Epub 2012 Mar 1.

PMID:
22387433
12.

Metabolism of cryptolepine and 2-fluorocryptolepine by aldehyde oxidase.

Stell JG, Wheelhouse RT, Wright CW.

J Pharm Pharmacol. 2012 Feb;64(2):237-43. doi: 10.1111/j.2042-7158.2011.01408.x. Epub 2011 Nov 18.

PMID:
22221099
13.

Probing the molecular recognition of a DNA.RNA hybrid duplex.

Wheelhouse RT, Garbett NC, Buurma NJ, Chaires JB.

Angew Chem Int Ed Engl. 2010 Apr 19;49(18):3207-10. doi: 10.1002/anie.200907235. No abstract available.

14.

Drug binding to DNA x RNA hybrid structures.

Wheelhouse RT, Chaires JB.

Methods Mol Biol. 2010;613:55-70. doi: 10.1007/978-1-60327-418-0_4.

15.

Inhibition of cobalamin-dependent methionine synthase by substituted benzo-fused heterocycles.

Banks EC, Doughty SW, Toms SM, Wheelhouse RT, Nicolaou A.

FEBS J. 2007 Jan;274(1):287-99.

16.

Design, synthesis, and evaluation of novel biarylpyrimidines: a new class of ligand for unusual nucleic acid structures.

Wheelhouse RT, Jennings SA, Phillips VA, Pletsas D, Murphy PM, Garbett NC, Chaires JB, Jenkins TC.

J Med Chem. 2006 Aug 24;49(17):5187-98.

PMID:
16913707
17.

Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.

Pletsas D, Wheelhouse RT, Pletsa V, Nicolaou A, Jenkins TC, Bibby MC, Kyrtopoulos SA.

Eur J Med Chem. 2006 Mar;41(3):330-9. Epub 2006 Feb 3.

PMID:
16458393
18.

In-vitro cytotoxic activities of the major bromophenols of the red alga Polysiphonia lanosa and some novel synthetic isomers.

Shoeib NA, Bibby MC, Blunden G, Linley PA, Swaine DJ, Wheelhouse RT, Wright CW.

J Nat Prod. 2004 Sep;67(9):1445-9.

PMID:
15387639
19.

Biarylpyrimidines: a new class of ligand for high-order DNA recognition.

Murphy PM, Phillips VA, Jennings SA, Garbett NC, Chaires JB, Jenkins TC, Wheelhouse RT.

Chem Commun (Camb). 2003 May 21;(10):1160-1.

PMID:
12778714

Supplemental Content

Loading ...
Support Center